Phuturdex › Drugs › Somatropin
Drugs in development · updated 11 November 2026
Somatropin: clinical trials and development status
Other names and codes: Growth Hormone, Recombinant human growth hormone, Accretropin, Omnitrope, NutropinAq
As of 11 November 2026 Somatropin is in 8 active clinical trials (recruiting or ongoing, phases I–III) for 12 diseases. The most advanced phase is III.
Authorisation
- EU yes, since 15 Feb 2001 (EMA)
- Italy yes (EU authorisation)
- Germany yes (EU authorisation)
- US yes (FDA)
Sources: EMA, AIFA register (open data), FDA. For Germany only the EU centralised authorisation is shown: the national BfArM register is not one of our sources.
Map of sites in Europe with recruitment status, every trial and an email when something changes. Full access free until 31 March 2027, no card needed.
What it is
A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Dwarfism, Pituitary | III | 2 | NCT04867317 |
| Growth disorder | III | 2 | NCT06103513 |
| Concussion | III | 1 | NCT04867317 |
| Gulf War syndrome | II | 1 | NCT05355272 |
| Knee osteoarthritis | I–II | 1 | NCT07036003 |
| Diabetes | I | 1 | NCT06558422 |
| Hyperinsulinism | I | 1 | NCT06558422 |
| Insulin resistance | I | 1 | NCT06558422 |
| Non-alcoholic Fatty Liver Disease | I | 1 | NCT06558422 |
| Obesity | I | 1 | NCT06558422 |
| Prediabetes | I | 1 | NCT06558422 |
| Gastroparesis | Early I | 1 | NCT06803589 |
Everything on Somatropin
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 11 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, refers to the United States and is a Phuturdex calculation described on the Method page, not official data: the drug may already be marketed in other countries.